Перевести на Переведено сервисом «Яндекс.Перевод»

Analyst recommendations

The biotechnology sector has been incredibly successful in 2014 year. Its growth outperformed the growth of S&P 500  stunning 36%. Analysts at JP Morgan believe that a huge priority sector dynamics can decrease in 2015 year, but may remain the same level. The main drivers the success of biotech in 2014 were a high demand for the main products of the sector, the positive results of many clinical studies phase a wave of successful initial public offerings.
Date Company Who recommends Recommendation Target price
Johnson & Johnson Deutsche Bank Buy 105
Endo International plc Deutsche Bank Buy 88
Becton, Dickinson and Company Deutsche Bank Buy 167
CVS Health Corporation Deutsche Bank Buy 118
Pfizer Inc. Morgan Stanley Buy 43
Bristol-Myers Squibb Company Morgan Stanley Buy 80
DENTSPLY International Inc. Morgan Stanley Buy 70
UnitedHealth Group Incorporated Morgan Stanley Buy 140
Anthem, Inc. RBC Capital Mkts Buy 198
Edwards Lifesciences Corp. RBC Capital Mkts Buy 160
DaVita HealthCare Partners Inc. RBC Capital Mkts Buy 83
Express Scripts Holding Company RBC Capital Mkts Buy 95
HCA Holdings, Inc. UBS Buy 90
AbbVie Inc. UBS Buy 78
Merck & Co. Inc. UBS Buy 68
Celgene Corporation UBS Buy 156
Alexion Pharmaceuticals, Inc. UBS Buy 223
PerkinElmer Inc. UBS Buy 60
1 2